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M
yelodysplasia (MDS) is 
a clonal hematopoietic 
malignancy as stubborn in 
revealing its pathogenesis as it is in 
responding to treatment. The disease 
presents with cytopenia of any or all of 
the three hematopoietic lineages (red 
blood cells, platelets, and white blood 
cells), manifesting clinically as fatigue, 
bleeding, and infectious disorders. 
While the disease occurs in only ﬁve 
per 100,000 people, its incidence 
rises steeply with age, reaching about 
20–40 per 100,000 at age 70 years and 
beyond. Thus, as the population ages, 
the impact of MDS on the health care 
system will grow. 
The natural history of MDS is 
highly variable. By deﬁnition, cases 
present with low blood counts. 
Without treatment (and often, despite 
treatment), patients will embark on 
one of two paths of disease course, 
both inevitably fatal. Many will have 
progressive cytopenias, and eventually 
succumb to bleeding and infection 
complications. Other patients progress 
to acute myeloid leukemia (AML). 
Unlike “de novo” AML (where the 
patient presents with leukemia 
without an antecedent history of a 
hematopoietic disorder), which can 
be cured with high-dose combination 
chemotherapy in about 25% of cases, 
the “secondary” AML that arises from 
MDS is incurable by chemotherapy [1]. 
Classiﬁcation and Prognosis
The diagnosis of MDS requires the 
bone marrow evidence of dysplasia 
(abnormal appearing cells) in at least 
one of the hematopoietic cell lineages. 
Approximately 50% of cases will have 
chromosomal abnormalities. The 
appearance of bone marrow “blasts” 
(immature progenitor cells) can be 
normal in many cases, if the blasts 
represent less than 5% of total bone 
marrow cells; increasing blasts herald 
a progression towards AML. Sensitive 
ﬂow cytometric analysis of cell surface 
antigens often shows a population 
of cells displaying an abnormal 
constellation of antigens, further 
evidence of disturbed hematopoiesis. 
Diagnostic and classiﬁcation schemes 
are based on the extent of cytopenia, 
cytogenetic abnormalities, blast 
percentages, and other morphological 
features. The older French, American, 
and British (FAB) diagnostic system 
divided the disease into refractory 
anemia (RA), where blast counts were 
<5%; RA with ringed sideroblasts 
(RARS); and two classes with increasing 
blast counts, RA with excessive blasts 
of >5% (RAEB), and with excessive 
blasts (>20%) in “transition” to AML 
(RAEBT). Secondary AML arising from 
MDS was deﬁned as a marrow blast 
count of >30% [2]. Recently, the World 
Health Organization has reclassiﬁed 
MDS, dividing RA into groups with one 
or several cytopenias, and changing the 
cut-off of transition to AML to 20%, 
thus eliminating the RAEBT category 
in the FAB scheme [3]. In addition, a 
separate diagnosis is made for patients 
with the syndrome of a deletion in the 
5q chromosome (del(5q)) and <5% 
blasts, with normal or increased platelet 
counts. As with all classiﬁcation (and 
reclassiﬁcation) schemes, these are 
based on correlations with outcome, 
rather than the underlying biology of 
the disease.
The International Prognostic Scoring 
System uses a few simple variables to 
predict outcome (Tables 1 and 2) [4]. 
The percentage of marrow blasts, the 
presence of cytogenetic abnormalities 
(lumped into good, poor, and 
intermediate), and the number of 
cytopenias is used to derive a score 
that places patients into four risk 
categories. These outcomes are based 
on supportive care therapy. For low-risk 
disease, the median survival is 5.7 years; 
for intermediate risk-1, 3.5 years; for 
intermediate risk-2, 1.1 years; and for 
high risk, less than six months. 
The Biology of MDS
The biology driving MDS has been 
elusive, and has greatly undermined 
attempts to devise rational treatment 
options. Any biological model of 
MDS must explain several features 
of the disease: The paradox that 
early in disease patients appear to 
have increased proliferation and
apoptosis; the variable natural history 
of disease, from progressive cytopenia 
to progression to AML; and the 
potential contribution of the stromal 
environment to disease maintenance 
and progression. 
The genes and pathways involved 
in MDS are unclear [5]. Compared to 
AML, MDS tends to have more deletions 
of chromosomes (-5, -5q, -7, -7q, +8, 11q-, 
20q-), implicating tumor suppressor 
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Linked Research Article
This Research in Translation article 
discusses the following new study 
published in PLoS Medicine:
Ebert BL, Galili N, Tamayo P, 
Bosco J, Mak R, et al. (2008) An 
erythroid differentiation signature 
predicts response to lenalidomide 
in myelodysplastic syndrome. PLoS 
Med 5(2): e35. doi:10.1371/journal.
pmed.0050035
Using gene expression proﬁling, 
Azra Raza and colleagues identiﬁed 
a molecular signature that predicts 
response to lenalidomide in patients 
without Chromosome 5q deletions, 
which suggests that these patients have 
a defect in erythroid differentiation.PLoS Medicine  |  www.plosmedicine.org 0200 February 2008  |  Volume 5  |  Issue 2  |  e40
genes, though the genes have not 
been identiﬁed [6]. Compared to 
AML, mutations or deletions involving 
tyrosine kinases, the ras pathway, and 
transcription factors are unusual (Figure 
1). Recently, gene expression arrays 
have found that the progression of MDS 
from RA to advanced phases of MDS is 
associated with the aberrant expression 
of genes associated with proliferation 
(e.g., c-myb) and differentiation (e.g., α, 
β, and δ-globin) [7]. 
Therapy for MDS
The quest for effective therapy for MDS 
has been disappointing. Secondary 
AML is especially problematic, since 
at this stage of MDS, the reserve of 
normal hematopoietic cells is marginal, 
and thus after chemotherapy, patients 
suffer from prolonged cytopenias since 
they lack the ability to muster normal 
hematopoiesis. Attempts to adjust and 
apply conventional AML therapy to 
MDS (e.g, low-dose Ara-C) have given 
uninspiring results.
There is a current wave of new 
approaches aimed at greater 
effectiveness that target other biological 
pathways. In general, all therapies 
work better with early disease (RA) 
compared with advanced stage disease. 
However, the only curative therapy 
is allogeneic transplantation. This 
procedure has the obvious limitation 
of needing an appropriately human 
leukocyte antigen-matched donor, 
and is fraught with complications from 
the high-dose conditioning regimen, 
infections, and graft-versus-host disease. 
Nonetheless, about 60% of patients 
transplanted with RA are disease-free at 
ﬁve years. If transplantation is deferred 
to advanced stage disease, survival falls 
to around 20% [8–10]. Recently, low-
intensity transplants, which rely on 
the “graft-versus-leukemia” effect of 
the donor immune system against the 
malignancy, have been investigated. 
These transplants have quite similar 
results to the full myeloablative 
transplants, and can be given to an 
older population [11].
What about the vast majority 
of patients with MDS in whom 
transplantation is neither possible, 
nor preferred? A recent advance has 
been the introduction of the hypo-
methylating agents 5-azacitidine and 
5-aza-2’-deoxycytidine (decitidine) 
[12,13]. These agents cause a gradual 
change in the methylation status of 
the malignant clone, changing the 
expression of genes thought to be 
repressed from aberrant methylation-
mediated silencing. Several large 
studies have shown that these agents are 
effective, yielding complete response 
rates from around 20% to 40%. Patients 
on these therapies appear to have an 
approximately 18-month prolongation 
of their survival compared to patients 
receiving the standard of care, with an 
approximately 2-fold decrease in the 
rate of progression to AML. 
There are some data suggesting 
that MDS may be immunologically 
driven or modulated. Thus, 
attempts at immunoregulation 
using immunological agents such 
as cyclosporine and antithymocyte 
globulin are occasionally helpful. 
Likewise, antibody therapy directed 
at tumor necrosis factor receptors 
(Enbrel) shows some promise, causing 
correction in blood counts in about 
25% of cases [14,15]. The thalidomide 
derivative lenalidomide (Revlimid) has 
shown considerable promise in low-
risk MDS, especially in patients with 
del(5q). Lenalidomide appears to have 
immunomodulatory activity, as well as 
affecting cytokine and angiogenesis 
pathways. Lenalidomide appears 
remarkably selective for patients with 
del(5q), yielding complete cytogenetic 
responses in nearly 60% of patients. In 
addition, around 70% of patients had 
a decline in transfusion needs, while 
only about 25% of patients without the 
del(5q) enjoyed this beneﬁt [16,17]. 
In Search of Better Therapies for 
MDS
The recent excitement over modest 
response rates reﬂects long-standing 
frustration (if not desperation) in 
treating MDS. How do we ﬁnd better 
therapies? A fundamental building 
block would be the understanding of 
why certain therapies work in a subset 
of patients. In this light, the work by 
Azra Raza and colleagues in this issue 
of PLoS Medicine is a strong step towards 
understanding the biology underlying 
treatment response in MDS [18]. The 
authors studied the gene expression 
signature associated with lenalidomide 
response in low-risk MDS. They ﬁrst 
established the response signature 
in low-risk non-5q- MDS patients, 
and used a validation set of 5q- and 
doi:10.1371/journal.pmed.0050040.g001
Figure 1. The Percentage of Cases of MDS and AML Harboring Speciﬁc Classes of Genetic 
Mutations
Table 1. The International Prognostic Scoring System and Prognosis
Score
Prognostic Variable Score 0 Score 0.5 Score 1 Score 1.5 Score 2
Marrow blasts (%) <5 5–10 NA 11–20 21–30
Karyotypea Good Intermediate Poor  NA  NA
Cytopeniasb 0 or 1 2 or 3  NA  NA  NA
aGood = normal, -Y, del(5q), del(20) only; poor = complex (>3 abnormalities), del(7); intermediate = all other chromosomal 
changes.
bNeutrophil <1,800 /µl; platelets <100,000 /µl; hemoglobin <10 mg/dl.
NA, not applicable.
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non-5q-patients. They found that the 
gene expression response signature 
was enriched in genes involved in 
erythroid differentiation; as a biological 
conﬁrmation, the authors demonstrate 
that the application of lenalidomide 
to primary non-MDS CD34+ cells 
promoted erythroid differentiation. 
The study has a few limitations, but 
these do not retract from the ﬁndings 
or their signiﬁcance. The study is fairly 
small, and thus may not be robust in 
regards to predicting response in a 
larger, more heterogeneous group. The 
arrays were performed on mononuclear 
samples, rather than puriﬁed CD34+
cells. While critics may cite this as a 
problem of deriving an expression 
signature from a heterogeneous sample, 
the potential advantage biologically is 
that the inclusion of the entire marrow 
sample studies the gene expression 
changes seen across the population, 
which may give a truer glimpse of the 
biology of the disease. From a practical 
side, the simpler sample is preferred, 
since if these studies are ever to be used 
for diagnostic purposes, an analysis of 
the restricted CD34+ population would 
be impractical.
The study is important on several 
fronts. First, the determination of 
a lenalidomide response signature 
may be important in selecting non-
5q patients that will respond to that 
therapy. This will improve the MDS 
response rate to lenalidomide in the 
community by “enriching” for patients 
who should actually respond to the 
drug. It also points to an important 
pathway (erythroid differentiation) as 
a target for future drug development. 
Moreover, the approach outlined 
by the investigators should serve as 
a model for probing the genetics of 
response in other MDS therapy. One 
can imagine the day when small sets of 
genes can be used at diagnosis to guide 
the choice of therapeutic options. 
Conclusion
The treatment of MDS is still distinctly 
suboptimal. New agents have 
brightened the picture, and studies 
such as that of Raza et al. promise to 
focus therapy on those patients who 
will most likely beneﬁt. Nonetheless, 
substantial obstacles still confront 
us. We have little understanding of 
why MDS is age related; why patients 
progress to AML, and how to predict 
or prevent it; the relative roles of 
the MDS clonal cell and the stromal 
environment in determining response 
and progression; and how to add 
combinations of agents to better treat 
MDS. There is much to do, and the 
clock is running: we are all getting 
older, and MDS is waiting.  
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Six Key Papers in the Field
Kantarjian et al., 2007 [12] and 
Silverman et al., 2002 [13] These two 
papers show the promise of the new 
demethylating agents, which are one of 
the few classes of drugs that appear to 
extend the natural history of MDS.
List et al., 2006 [16] This paper 
demonstrates the remarkable effect of 
lenalidomide on a speciﬁc subgroup of 
MDS.
Vardiman et al., 2002 [3] This paper 
updates the FAB classiﬁcation system, 
and attempts to further deﬁne MDS risk 
groups based on clinical and pathological 
features.
Greenberg et al., 1997 [4] This paper 
provides a natural history prognosis 
based only on the number of cytopenias, 
chromosomal abnormalities, and blast 
count.
Anderson et al., 1993 [8] One of the 
ﬁrst papers to give compelling evidence 
that allogeneic transplantation was 
potentially curative for MDS. 
Table 2. Risk Category and Prognosis
Risk Category Overall Score Median Survival (Years) Time to AML 
Progression (Months)a
Low risk 0 5.7 9.4
Intermediate-1 risk 0.5–1.0 3.5 3.3
Intermediate-2 risk 1.5–2.0 1.1 1.1
High risk >2.5 0.4 0.2
aMedian time for 25% of patients to progress to AML.
doi:10.1371/journal.pmed.0050040.t002